Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;23(5):493-500.

Cost-utility analysis of neonatal screening program, shiraz university of medical sciences, shiraz, iran, 2010

Affiliations

Cost-utility analysis of neonatal screening program, shiraz university of medical sciences, shiraz, iran, 2010

Nahid Hatam et al. Iran J Pediatr. 2013 Oct.

Abstract

Objective: The most important cause of infant mortality during the first month of life is related to congenital abnormalities. Nevertheless, timely diagnosis of these diseases can reduce the severity of their effects. The present study aimed to investigate the cost-effectiveness of the neonatal screening program in Fars Province, Iran.

Methods: In this study, costs of executing the screening programs, treatment of the diagnosed cases, treatment of affected, non-screened individuals, quality of life, and incremental cost-effectiveness ratios were measured in two study groups.

Findings: Performing the screening programs for phenylketonuria, congenital hypothyroidism, galactosemia, and favism resulted in respectively $3386, $13078, $19641, and $1088 saving per patient. Overall, the study results revealed the cost-effectiveness of execution of the neonatal screening program.

Conclusion: Neonatal screening program is one of the health interventions which lead to long-term beneficial outcome for the patients, financial saving for the society, and improvement of the patients' quantity as well as quality of life.

Keywords: Congenital Hypothyroidism; Cost-utility Analysis; Economic Evaluation; Favism; Galactosemia; Phenylketonuria; Screening.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Decision Tree for Neonatal Screening Programme for Phenylketonuria (PKU), Congenital hypothyroidism (CH), Galactosemia (GAL), Favism (G6PDD), No diagnosis at birth (No Dx).

Similar articles

Cited by

References

    1. Smith LK, Budd JL, Field DJ, et al. Socioeconomic inequalities in outcome of pregnancy and neonatal mortality associated with congenital anomalies: population based study. BMJ. 2011;343:d4306. - PMC - PubMed
    1. Burgard P, Rupp K, Lindner M, et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2. From screening laboratory results to treatment, follow-up and quality assurance. J Inherit Metab Dis. 2012;35(4):613–25. - PubMed
    1. Delavari A, Yar Ahmadi Sh, Birjandi R, et al. Cost-Benefit Analysis of the Neonatal Screening Program Implementation for Congenital Hypothyroidism in I. R. Iran. Int J Endocrinol Metab. 2006;4:84–87.
    1. Downing M, Pollitt R. Newborn bloodspot screening in the UK--past, present and future. Ann Clin Biochem. 2008;45(Pt 1):11–7. - PubMed
    1. World Health Organization (WHO) Control of Genetic Diseases. http://apps.who.int/gb/archive/pdf_files/EB116/B116_3-en.pdf. Assess date: Jul 26, 2013.

LinkOut - more resources